Table 1 – Patient demographics and clinical characteristics by COMT status and treatment arm.
|
COMT rs4680 (AA genotype) |
Wildtype COMT (GG or GA genotype) |
|||
|---|---|---|---|---|
| ADT + D (n = 70) | ADT alone (n = 53) | ADT + D (n = 214) | ADT alone (n = 213) | |
| Age (yr) | ||||
| Mean (standard deviation) | 63.9 (7.37) | 62.7 (9.21) | 63.0 (8.68) | 62.5 (8.94) |
| Median (range) | 63.5 (47–79) | 63.0 (44–84) | 64.0 (42–88) | 63.0 (39–91) |
| ECOG PS, n (%) | ||||
| 0 | 51 (72.9%) | 39 (73.6%) | 154 (72.0%) | 155 (73.1%) |
| 1–2 | 19 (27.1%) | 14 (26.4%) | 60 (28.0%) | 57 (26.9%) |
| Data missing | 0 | 0 | 0 | 1 |
| Metastasis volume, n (%) | ||||
| High | 45 (64.3%) | 32 (60.4%) | 143 (66.8%) | 135 (63.4%) |
| Low | 25 (35.7%) | 21 (39.6%) | 71 (33.2%) | 78 (36.6%) |
| Gleason score, n (%) | ||||
| ≤7 | 20 (33.3%) | 15 (31.9%) | 64 (32.2%) | 61 (32.1%) |
| 8–10 | 40 (66.7%) | 32 (68.1%) | 135 (67.8%) | 129 (64.8%) |
| Data missing | 10 | 6 | 15 | 23 |
| Prior local treatment, n (%) | ||||
| No | 51 (72.9%) | 34 (64.2%) | 152 (71.0%) | 146 (68.9%) |
| Yes | 19 (27.1%) | 19 (35.8%) | 62 (29.0%) | 66 (31.1%) |
| Data missing | 0 | 0 | 0 | 1 |
ADT = androgen deprivation therapy; + D = with docetaxel; ECOG PS = Eastern Cooperative Oncology Group performance status.